Successful conversion surgery following chylous ascites after nivolumab for advanced gastric cancer

Satoshi Toyota, Hiroyuki Orita, Yasuro Fukuyama, Saki Motoyoshi, Shogo Kawanami, Shohei Maeda, Erina Kuramitsu, Michihiro Ichimanda, Satoko Nagamatsu, Shigeyuki Nagata, Seiichiro Kai, Daisuke Korenaga, Masaki Mori

Research output: Contribution to journalArticle

Abstract

Case Report: A 75-year-old man who underwent nivolumab as the third-line chemotherapy for advanced gastric cancer had chylous ascites (CA) after the primary tumor shrank remarkably. Total parenteral nutrition and subcutaneous octreotide were initiated, and CA disappeared. Nivolumab was continued for a total of 23 courses. Computed tomography showed lymph node swelling; however, staging laparoscopy showed that peritoneal metastasis had disappeared. Therefore, conversion surgery and distal gastrectomy with D1+ dissection were performed. Results: The pathological diagnosis was type IV, poorly differentiated adenocarcinoma (por2) with signet ring cells, ypT2 (muscularis propria), without lymphatic or venous invasion, and no involvement of the proximal and distal margins. After the operation, no recurrence was observed over 7 months with no adjuvant chemotherapy. Conclusion: Nivolumab has the potential to lead to R0 resection for patients with peritoneal carcinomatosis gastric cancer. To our knowledge, this is the first report of successful conversion surgery after nivolumab-related chylous ascites.

Original languageEnglish
Pages (from-to)583-585
Number of pages3
JournalIn Vivo
Volume34
Issue number2
DOIs
Publication statusPublished - Jan 1 2020

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this